secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001140361-25-017615
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore Q1: KIMMTRAK revenue $93.9M (+33% YoY); net income $5M vs loss year ago
--------------------------------------------------------------------------------

- KIMMTRAK net sales $93.9M, up 33% YoY; US $56.6M, Europe $32.8M (incl $6M favorable adjustments), intl $4.5M.
- Net income $5.0M vs net loss $24.4M in Q1 2024; diluted EPS $0.10 vs ($0.49).
- Phase 3 TEBE-AM (cutaneous melanoma) enrollment on track to complete in 1H 2026; PRISM-MEL-301 dose selection expected 2H 2025.
- HIV candidate IMC-M113V showed viral control in 3 of 15 evaluable patients at CROI; dose escalation continuing.
- Cash and securities $837M at March 31, 2025, up from $820.4M at Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125017615/0001140361-25-017615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125017615/ef20048471_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-017615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer